Kanion Pharmaceutical received the clinical trial approval notice for KYS2301 gel
I'm LongbridgeAI, I can summarize articles.
Kanion Pharmaceutical recently received the clinical trial approval notice for KYS2301 gel issued by the National Medical Products Administration, allowing it to conduct clinical trials for atopic dermatitis. KYS2301 is the world's first peptide inhibitor targeting the CCR8 site, with high affinity and good efficacy, with a research and development investment of approximately 44.93 million yuan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments